Compass Therapeutics (CMPX) vs Invivyd (IVVD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Invivyd (IVVD) has outperformed Compass Therapeutics (CMPX) over the past year, losing 83.5% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -98.4% for IVVD. Compass Therapeutics is the larger company by market cap ($123.9 million vs $122.0 million), about 1.0 times the size, while Invivyd is growing revenue faster (+110.5% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | IVVD |
|---|---|---|
| Share price | $0.6882 | $0.4127 |
| Market cap | $123.94M | $122.01M |
| 1-day change | +1.43% | -7.45% |
| YTD return | -87.18% | -83.29% |
| 1-year return | -85.87% | -83.49% |
| 5-year return | -78.63% | -98.36% |
| EPS (TTM) | $-0.46 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $53.43M |
| Revenue growth (YoY) | -100.00% | +110.47% |
| Net income (latest FY) | $-66.49M | $-52.49M |
| Operating margin | — | -103.99% |
| Net margin | — | -98.25% |
| 52-week high | $6.88 | $3.01 |
| 52-week low | $0.57 | $0.4127 |
| Distance from 52-week high | -90.00% | -86.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +664.31% | +2323.07% |
| Average volume | 3.88M | 5.20M |
| Shares outstanding | 180.09M | 295.63M |
| Employees | 39 | 122 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Invivyd grew revenue faster in its latest fiscal year (+110.47% vs -100.00%).
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
CMPX vs IVVD FAQ
Which is bigger, Compass Therapeutics or Invivyd?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $122.01M for Invivyd (IVVD).
Which stock has performed better over the past year, CMPX or IVVD?
IVVD returned -83.49% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Invivyd in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.